Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Durvalumab
Monoclonal Antibody · Antineoplastic
Monoclonal AntibodyAntineoplastic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Durvalumab is a human monoclonal antibody that selectively binds to programmed cell death ligand-1 (PD-L1), blocking its interaction with the programmed death-1 (PD-1) receptor and with CD80, and thereby potentiating an immune response to tumour cells.
Indications
Non-small cell lung cancer (initiated by a specialist)cancer therapymetastatic urothelial canceradvanced NSCLCfirst-line treatment of small cell lung cancer (with etoposide and either carboplatin or cisplatin)
Dosing
- Adult
- 10 mg/kg every 2 weeks, by intravenous infusion
Side effects
Common
Coughdiarrhoeadysphoniadysuriafeverflank paingastrointestinal discomfortgastrointestinal disordershyperthyroidismhypothyroidismincreased risk of infectioninfusion related reactionmyalgianight sweatsperipheral oedemarespiratory disordersskin reactionsthyroiditis
Serious
- Adrenal insufficiency
- glomerulonephritis
- hepatic disorders
- myopathy
- nephritis
- type 1 diabetes mellitus
- diabetes insipidus
- hypophysitis
- hypopituitarism
- myocarditis
- immune-related reactions
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Clinical effect not specified
Source: DDInter
Fingolimod
Severe
Database
Clinical effect not specified
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Lenalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Durvalumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team